This post originally appeared on Fast Data Science’s blog on LinkedIn.
Clinical trials, the backbone of medical science advancement, often grapple with high costs, complexity, and lengthy timelines. Fast Data Science presents Fast Clinical AI, a game-changing solution that harnesses the power of Natural Language Processing (NLP) and predictive modelling to tackle these challenges head-on.
Fast Clinical AI automates the extraction of critical information from trial protocols, significantly reducing manual efforts. This tool identifies risk factors and predicts costs and enrolment criteria, ensuring efficient trial planning and execution.
By identifying potential risks early in the trial process, Fast Clinical AI allows researchers to take proactive measures, minimising the chances of trial delays or failures. This proactive approach ensures that trials are faster and more reliable.
Fast Clinical AI helps predict and manage the costs associated with clinical trials, ensuring better resource allocation. Reducing manual efforts and streamlining processes significantly reduces the time required to bring new treatments to market.
Explore how Fast Clinical AI can revolutionise your clinical trials. Visit here for more details. Learn more about clinical trial cost modelling with NLP and AI here. Connect with us today to see how we can support your clinical trial efforts. Let’s innovate together!
#ClinicalTrials #AI #NLP #HealthcareInnovation #FastClinicalAI
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction The success of clinical studies relies heavily on proper financial planning and budgeting. These processes directly impact key factors such as project timelines, resource allocation, and compliance with regulatory requirements. The accurate forecasting of costs for clinical trials, however, is a highly complex and resource-intensive process. A study by the Tufts Center for the Study of Drug Development found that the average cost of developing a new drug is approximately $2.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction Recent years have seen a substantial rise in oncology clinical trials, with annual growth exceeding 260 studies on average [1]. Despite this increase, these studies continue to be some of the most demanding and resource-intensive in clinical research. The combination of intensive monitoring, detailed assessment schedules, and highly specific eligibility criteria creates substantial operational challenges.
Guest post by Safeer Khan, Lecturer at Department of Pharmaceutical Sciences, Government College University, Lahore, Pakistan Introduction In recent years, the cost of conducting clinical trials has risen dramatically. This increase has posed a significant challenge for pharmaceutical companies, researchers, and healthcare innovators. According to a study published in Nature Reviews in 2017, the median cost of conducting a study was $3.4 million for phase I trials, $8.6 million for phase II trials, and $21.
